Tumor Development Under Combination Treatments with Anti-angiogenic Therapies

[1]  Urszula Ledzewicz,et al.  Multi-input Optimal Control Problems for Combined Tumor Anti-angiogenic and Radiotherapy Treatments , 2012, J. Optim. Theory Appl..

[2]  Urszula Ledzewicz,et al.  Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis. , 2011, Mathematical biosciences and engineering : MBE.

[3]  Antonio Fasano,et al.  A generalization of Gompertz law compatible with the Gyllenberg-Webb theory for tumour growth. , 2011, Mathematical biosciences.

[4]  Alberto Gandolfi,et al.  Resistance to antitumor chemotherapy due to bounded-noise-induced transitions. , 2010, Physical review. E, Statistical, nonlinear, and soft matter physics.

[5]  Urszula Ledzewicz,et al.  Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment. , 2010, Mathematical medicine and biology : a journal of the IMA.

[6]  Alberto Gandolfi,et al.  Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular "pruning". , 2010, Journal of theoretical biology.

[7]  Wim Michiels,et al.  Recent Advances in Optimization and its Applications in Engineering , 2010 .

[8]  A. d’Onofrio,et al.  Resistance to anti-tumor chemotherapy due to bounded-noise transitions , 2010 .

[9]  Urszula Ledzewicz,et al.  Minimizing Tumor Volume for a Mathematical Model of Anti-Angiogenesis with Linear Pharmacokinetics , 2010 .

[10]  A. Świerniak,et al.  Mathematical modeling as a tool for planning anticancer therapy. , 2009, European journal of pharmacology.

[11]  H. Schättler,et al.  On optimal delivery of combination therapy for tumors. , 2009, Mathematical biosciences.

[12]  A. d’Onofrio.  Fractal growth of tumors and other cellular populations : linking the mechanistic to the phenomenological modeling and vice versa , 2014 .

[13]  Urszula Ledzewicz,et al.  Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models , 2009 .

[14]  A. Gandolfi,et al.  The dynamics of tumour–vasculature interaction suggests low‐dose, time‐dense anti‐angiogenic schedulings , 2009, Cell proliferation.

[15]  Alberto Gandolfi,et al.  A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. , 2008, Mathematical medicine and biology : a journal of the IMA.

[16]  Andrzej Świerniak.  Comparison of six models of antiangiogenic therapy , 2009 .

[17]  Urszula Ledzewicz,et al.  No . 4 B Singular controls and chattering arcs in optimal control problems arising in biomedicine , 2010 .

[18]  Urszula Ledzewicz,et al.  Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. , 2008, Journal of theoretical biology.

[19]  A. Świerniak,et al.  Direct and indirect control of cancer populations , 2008 .

[20]  Paolo Ubezio,et al.  Cell killing and resistance in pre-operative breast cancer chemotherapy , 2008, BMC Cancer.

[21]  D. Frame.  New Strategies in Controlling Drug Resistance , 2007, Journal of managed care pharmacy : JMCP.

[22]  Alberto d'Onofrio,et al.  Rapidly acting antitumoral antiangiogenic therapies. , 2007, Physical review. E, Statistical, nonlinear, and soft matter physics.

[23]  Urszula Ledzewicz,et al.  AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..

[24]  K. Hoo,et al.  Understanding the role of the tumour vasculature in the transport of drugs to solid cancer tumours , 2007, Cell proliferation.

[25]  J. Folkman.  Opinion: Angiogenesis: an organizing principle for drug discovery? , 2007, Nature Reviews Drug Discovery.

[26]  U. Ledzewicz,et al.  ANTI-ANGIOGENIC THERAPY IN CANCER TREATMENT AS AN OPTIMAL CONTROL PROBLEM , 2007 .

[27]  Alberto Gandolfi,et al.  The response to antiangiogenic anticancer drugs that inhibit endothelial cell proliferation , 2006, Appl. Math. Comput..

[28]  S. McDougall,et al.  Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. , 2006, Journal of theoretical biology.

[29]  Andrzej Swierniak,et al.  Control Theory Approach to Cancer Chemotherapy: Benefiting from Phase Dependence and Overcoming Drug Resistance , 2006 .

[30]  A. d’Onofrio.  A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.

[31]  P K Maini,et al.  A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results , 2005, Bulletin of mathematical biology.

[32]  Alberto Gandolfi,et al.  Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). , 2004, Mathematical biosciences.

[33]  Peteris Daugulis,et al.  Hopf point analysis for angiogenesis models , 2003 .

[34]  Ricard V. Solé,et al.  Phase transitions in unstable cancer cell populations , 2003 .

[35]  M Tubiana,et al.  Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  B Møller,et al.  Cancer mortality trends in the EU and acceding countries up to 2015. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  L. Wein,et al.  Optimal scheduling of radiotherapy and angiogenic inhibitors , 2003, Bulletin of mathematical biology.

[38]  Pier Paolo Delsanto,et al.  Does tumor growth follow a "universal law"? , 2003, Journal of theoretical biology.

[39]  J. Rak,et al.  Host microenvironment in breast cancer development: Inflammatory and immune cells in tumour angiogenesis and arteriogenesis , 2003, Breast Cancer Research.

[40]  Urszula Ledzewicz,et al.  OPTIMAL CONTROL FOR A CLASS OF COMPARTMENTAL MODELS IN CANCER CHEMOTHERAPY , 2003 .

[41]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[42]  Ney Lemke,et al.  A mean-field theory of cellular growth , 2002 .

[43]  Urszula Ledzewicz,et al.  ANALYSIS OF A CELL-CYCLE SPECIFIC MODEL FOR CANCER CHEMOTHERAPY , 2002 .

[44]  Urszula Ledzewicz,et al.  Optimal Bang-Bang Controls for a Two-Compartment Model in Cancer Chemotherapy , 2002 .

[45]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[47]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[48]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[49]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[50]  M. Chaplain,et al.  Continuous and discrete mathematical models of tumor-induced angiogenesis , 1998, Bulletin of mathematical biology.

[51]  Z. Agur,et al.  The growth law of primary breast cancer as inferred from mammography screening trials data. , 1998, British Journal of Cancer.

[52]  J C Panetta,et al.  A mathematical model of breast and ovarian cancer treated with paclitaxel. , 1997, Mathematical biosciences.

[53]  R. Kerbel.  A cancer therapy resistant to resistance , 1997, Nature.

[54]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[55]  U. Veronesi,et al.  Oxford textbook of oncology , 1996 .

[56]  Jaroslaw Smieja,et al.  Cell Cycle as an Object of Control , 1995 .

[57]  H. Bartelink,et al.  Fractionation in radiotherapy. , 1994, Cancer treatment reviews.

[58]  R K Sachs,et al.  Optimizing the time course of brachytherapy and other accelerated radiotherapeutic protocols. , 1994, International journal of radiation oncology, biology, physics.

[59]  Z Bajzer,et al.  Analysis of growth of multicellular tumour spheroids by mathematical models , 1994, Cell proliferation.

[60]  R. Tibshirani,et al.  An Introduction to the Bootstrap , 1995 .

[61]  Heinz Schättler,et al.  A synthesis of time-optimal controls in the presence of saturated singular arcs , 1993 .

[62]  G. W. Swan.  Role of optimal control theory in cancer chemotherapy. , 1990, Mathematical biosciences.

[63]  J. Fowler.  The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.

[64]  L. Norton.  A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[65]  T. Wheldon.  Mathematical models in cancer research , 1988 .

[66]  H. Skipper.  On mathematical modeling of critical variables in cancer treatment (goals: Better understanding of the past and better planning in the future) , 1986, Bulletin of mathematical biology.

[67]  L. Norton,et al.  The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.

[68]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[69]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[70]  L. Norton,et al.  Growth curve of an experimental solid tumor following radiotherapy. , 1977, Journal of the National Cancer Institute.

[71]  M Tatcher,et al.  [Fractionation in radiotherapy]. , 1972, Harefuah.

[72]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.

[73]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.